These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 12297059)

  • 1. Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence.
    Davies JC
    Paediatr Respir Rev; 2002 Jun; 3(2):128-34. PubMed ID: 12297059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence and persistence of Pseudomonas aeruginosa in the cystic fibrosis airway.
    Fick RB; Sonoda F; Hornick DB
    Semin Respir Infect; 1992 Sep; 7(3):168-78. PubMed ID: 1475541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung.
    Hogardt M; Heesemann J
    Curr Top Microbiol Immunol; 2013; 358():91-118. PubMed ID: 22311171
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Di Paola M; Park AJ; Ahmadi S; Roach EJ; Wu YS; Struder-Kypke M; Lam JS; Bear CE; Khursigara CM
    mBio; 2017 Dec; 8(6):. PubMed ID: 29259090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains.
    Varga JJ; Barbier M; Mulet X; Bielecki P; Bartell JA; Owings JP; Martinez-Ramos I; Hittle LE; Davis MR; Damron FH; Liechti GW; Puchałka J; dos Santos VA; Ernst RK; Papin JA; Albertí S; Oliver A; Goldberg JB
    BMC Genomics; 2015 Oct; 16():883. PubMed ID: 26519161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent infections and immunity in cystic fibrosis.
    Yu H; Head NE
    Front Biosci; 2002 Feb; 7():d442-57. PubMed ID: 11815305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies.
    Hassett DJ; Korfhagen TR; Irvin RT; Schurr MJ; Sauer K; Lau GW; Sutton MD; Yu H; Hoiby N
    Expert Opin Ther Targets; 2010 Feb; 14(2):117-30. PubMed ID: 20055712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacteriology and treatment of infections in the upper and lower airways in patients with primary ciliary dyskinesia: adressing the paranasal sinuses.
    Alanin MC
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis of the pseudomonas lung lesion in cystic fibrosis.
    Fick RB
    Chest; 1989 Jul; 96(1):158-64. PubMed ID: 2500307
    [No Abstract]   [Full Text] [Related]  

  • 10. Mouse models of chronic lung infection with Pseudomonas aeruginosa: models for the study of cystic fibrosis.
    Stotland PK; Radzioch D; Stevenson MM
    Pediatr Pulmonol; 2000 Nov; 30(5):413-24. PubMed ID: 11064433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Pseudomonas aeruginosa infection in cystic fibrosis airway disease: metabolic changes that unravel novel drug targets.
    Yoon SS; Hassett DJ
    Expert Rev Anti Infect Ther; 2004 Aug; 2(4):611-23. PubMed ID: 15482224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaerobic Pseudomonas aeruginosa and other obligately anaerobic bacterial biofilms growing in the thick airway mucus of chronically infected cystic fibrosis patients: an emerging paradigm or "Old Hat"?
    Su S; Hassett DJ
    Expert Opin Ther Targets; 2012 Sep; 16(9):859-73. PubMed ID: 22793158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the CFTR in susceptibility to Pseudomonas aeruginosa infections in cystic fibrosis.
    Goldberg JB; Pier GB
    Trends Microbiol; 2000 Nov; 8(11):514-20. PubMed ID: 11121762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies of Pseudomonas aeruginosa to colonize and to persist in the cystic fibrosis lung.
    Kubesch P; Lingner M; Grothues D; Wehsling M; Tümmler B
    Scand J Gastroenterol Suppl; 1988; 143():77-80. PubMed ID: 3133755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.
    Howlin RP; Cathie K; Hall-Stoodley L; Cornelius V; Duignan C; Allan RN; Fernandez BO; Barraud N; Bruce KD; Jefferies J; Kelso M; Kjelleberg S; Rice SA; Rogers GB; Pink S; Smith C; Sukhtankar PS; Salib R; Legg J; Carroll M; Daniels T; Feelisch M; Stoodley P; Clarke SC; Connett G; Faust SN; Webb JS
    Mol Ther; 2017 Sep; 25(9):2104-2116. PubMed ID: 28750737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycerol metabolism promotes biofilm formation by Pseudomonas aeruginosa.
    Scoffield J; Silo-Suh L
    Can J Microbiol; 2016 Aug; 62(8):704-10. PubMed ID: 27392247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.
    Sousa AM; Monteiro R; Pereira MO
    Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections.
    Ciofu O; Mandsberg LF; Wang H; Høiby N
    FEMS Immunol Med Microbiol; 2012 Jul; 65(2):215-25. PubMed ID: 22540844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.
    Li Z; Kosorok MR; Farrell PM; Laxova A; West SE; Green CG; Collins J; Rock MJ; Splaingard ML
    JAMA; 2005 Feb; 293(5):581-8. PubMed ID: 15687313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.